New data suggest that treatment with patiromer or sodium zirconium cyclosilicate for up to 8 weeks reduces plasma potassium levels in hyperkalaemic patients. If proven safe and effective for long-term use, these therapies might be administered together with intensive renin-angiotensin-aldosterone blockade to reduce adverse effects and renal and cardiovascular risk
INTRODUCTION: Hyperkalemia is a chronic and life-threatening electrolyte disorder that affects milli...
AIMS Hyperkalaemia risk precludes optimal renin-angiotensin-aldosterone system inhibitor use in pat...
Hyperkalemia may cause life-threatening cardiac and neuromuscular alterations, and it is associated ...
New data suggest that treatment with patiromer or sodium zirconium cyclosilicate for up to 8 weeks r...
Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctio...
Hyperkalaemia is a common complication in patients with nondialysis Chronic Kidney Disease (CKD). It...
International audienceChronic kidney disease (CKD) patients and more so CKD patients treated with re...
Hyperkalemia is an elevated level of serum potassium (K+) and does represent a life-threatening cond...
Purpose of reviewMedications used frequently after kidney transplantation, including calcineurin inh...
Pivotal randomized trials demonstrating efficacy, safety and good tolerance, of two new potassium bi...
Hyperkalemia is an elevated level of serum potassium (K+) and does represent a life-threatening cond...
Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medica...
What is Known and Objective Hyperkalaemia is a common medical emergency in patients admitted to hos...
Aims In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldost...
Heart failure (HF) is a worrisome cardiac pandemic with a negative prognostic impact on the overall ...
INTRODUCTION: Hyperkalemia is a chronic and life-threatening electrolyte disorder that affects milli...
AIMS Hyperkalaemia risk precludes optimal renin-angiotensin-aldosterone system inhibitor use in pat...
Hyperkalemia may cause life-threatening cardiac and neuromuscular alterations, and it is associated ...
New data suggest that treatment with patiromer or sodium zirconium cyclosilicate for up to 8 weeks r...
Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctio...
Hyperkalaemia is a common complication in patients with nondialysis Chronic Kidney Disease (CKD). It...
International audienceChronic kidney disease (CKD) patients and more so CKD patients treated with re...
Hyperkalemia is an elevated level of serum potassium (K+) and does represent a life-threatening cond...
Purpose of reviewMedications used frequently after kidney transplantation, including calcineurin inh...
Pivotal randomized trials demonstrating efficacy, safety and good tolerance, of two new potassium bi...
Hyperkalemia is an elevated level of serum potassium (K+) and does represent a life-threatening cond...
Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medica...
What is Known and Objective Hyperkalaemia is a common medical emergency in patients admitted to hos...
Aims In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldost...
Heart failure (HF) is a worrisome cardiac pandemic with a negative prognostic impact on the overall ...
INTRODUCTION: Hyperkalemia is a chronic and life-threatening electrolyte disorder that affects milli...
AIMS Hyperkalaemia risk precludes optimal renin-angiotensin-aldosterone system inhibitor use in pat...
Hyperkalemia may cause life-threatening cardiac and neuromuscular alterations, and it is associated ...
DOI
Add to ORKG